Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vivani Medical, a clinical-stage biopharmaceutical company, announced positive results from their first-in-human LIBERATE-1 study and preclinical data for their semaglutide implant (NPM-139), demonstrating sustained drug exposure and over 20% weight loss for one year. The company plans to initiate a Phase 1 clinical study in mid-2026 with anticipat…